JP4472988B2 - 固体剤形用の速溶性マトリックスとしての同時処理炭水化物の系 - Google Patents

固体剤形用の速溶性マトリックスとしての同時処理炭水化物の系 Download PDF

Info

Publication number
JP4472988B2
JP4472988B2 JP2003552271A JP2003552271A JP4472988B2 JP 4472988 B2 JP4472988 B2 JP 4472988B2 JP 2003552271 A JP2003552271 A JP 2003552271A JP 2003552271 A JP2003552271 A JP 2003552271A JP 4472988 B2 JP4472988 B2 JP 4472988B2
Authority
JP
Japan
Prior art keywords
mannitol
composition
sorbitol
tablet
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003552271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005520796A5 (enExample
JP2005520796A (ja
Inventor
ノーマン,ゲーリー・ティー
ヌグル,カリアン・エフ
アミン,アルン・エス
チャンダー,サラ
Original Assignee
エスピーアイ・ファーマ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26956682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4472988(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エスピーアイ・ファーマ・インコーポレーテッド filed Critical エスピーアイ・ファーマ・インコーポレーテッド
Publication of JP2005520796A publication Critical patent/JP2005520796A/ja
Publication of JP2005520796A5 publication Critical patent/JP2005520796A5/ja
Application granted granted Critical
Publication of JP4472988B2 publication Critical patent/JP4472988B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003552271A 2001-12-17 2002-12-17 固体剤形用の速溶性マトリックスとしての同時処理炭水化物の系 Expired - Lifetime JP4472988B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34136601P 2001-12-17 2001-12-17
US10/274,227 US7118765B2 (en) 2001-12-17 2002-10-18 Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
PCT/US2002/040506 WO2003051338A1 (en) 2001-12-17 2002-12-17 Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms

Publications (3)

Publication Number Publication Date
JP2005520796A JP2005520796A (ja) 2005-07-14
JP2005520796A5 JP2005520796A5 (enExample) 2005-12-22
JP4472988B2 true JP4472988B2 (ja) 2010-06-02

Family

ID=26956682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003552271A Expired - Lifetime JP4472988B2 (ja) 2001-12-17 2002-12-17 固体剤形用の速溶性マトリックスとしての同時処理炭水化物の系

Country Status (9)

Country Link
US (4) US7118765B2 (enExample)
EP (1) EP1465604B1 (enExample)
JP (1) JP4472988B2 (enExample)
AU (1) AU2002351396B2 (enExample)
CA (1) CA2470601C (enExample)
ES (1) ES2429529T3 (enExample)
MX (1) MXPA04005955A (enExample)
WO (1) WO2003051338A1 (enExample)
ZA (1) ZA200404998B (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1128817A1 (en) * 1998-10-27 2001-09-05 Biovail Technologies Ltd Microparticles containing peg and/or peg glyceryl esters
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
FR2834894B1 (fr) * 2002-01-21 2004-02-27 Servier Lab Composition pharmaceutique orodispersible de piribedil
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
US7282217B1 (en) * 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
US8349361B2 (en) 2003-10-15 2013-01-08 Fuji Chemical Industry Co., Ltd. Composition for rapid disintegrating tablet in oral cavity
EP1715853A4 (en) * 2004-02-17 2012-07-18 Transcept Pharmaceuticals Inc COMPOSITIONS FOR THE DISTRIBUTION OF HYPNOTICS IN THE FIELD OF MUNICHCHLEIMHÄUTE AND USE METHOD THEREOF
US20050214365A1 (en) * 2004-03-24 2005-09-29 Gulf Pharmaceutical Industries [Instant dissolving tablet composition for loratidine and desloratidine]
EA013211B1 (ru) * 2004-07-01 2010-04-30 Лек Фармасьютиклз Д.Д. Быстрораспадающаяся диспергирующаяся во рту лекарственная форма и способ ее приготовления
ATE521343T1 (de) * 2004-11-24 2011-09-15 Teva Pharma Im mund zerfallende zusammensetzungen von rasagilin
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
US20060263427A1 (en) * 2005-05-03 2006-11-23 Roberts Richard H Quinine formulations
CN1686089B (zh) * 2005-05-08 2010-08-18 北京健健康康生物技术有限公司 一种可直接压片的木糖醇颗粒及其制备方法
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20070123562A1 (en) 2005-05-25 2007-05-31 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the-night insomnia
IL169678A (en) 2005-07-14 2010-11-30 Innova Sa Sweetener compositions
WO2007039075A2 (en) * 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
US20070092553A1 (en) * 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8425935B2 (en) * 2005-12-21 2013-04-23 Basf Se Pharmaceutical formulation for producing rapidly disintegrating tablets
FR2898492B1 (fr) * 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa Comprimes orodispersibles de domperidone
JP5535616B2 (ja) 2006-03-31 2014-07-02 ルビコン リサーチ プライベート リミテッド 口腔内崩壊錠剤のための直接圧縮性複合材
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
WO2008089772A1 (fr) * 2007-01-22 2008-07-31 Crd Saidal Formulation d'un comprime orodispersible a base d'acide acetylsalicylique enrobe
WO2008089773A1 (fr) * 2007-01-22 2008-07-31 Crd Saidal Formulation d'une matrice a desintegration rapide
WO2008148742A2 (de) 2007-06-06 2008-12-11 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
JP5420535B2 (ja) * 2007-06-06 2014-02-19 ビーエーエスエフ ソシエタス・ヨーロピア 速崩性錠剤製造のための医薬製剤
US8568780B2 (en) 2007-06-06 2013-10-29 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
EP2042160A1 (de) * 2007-09-14 2009-04-01 Basf Se Mittel für die Behandlung von Mund und Rachen in Form von Tabletten
DE102008012295A1 (de) 2008-03-03 2009-09-17 Südzucker AG Mannheim/Ochsenfurt Gemisch zur Herstellung von schnell zerfallenden Tabletten
WO2009124357A1 (en) * 2008-04-10 2009-10-15 Malvin Leonard Eutick Fast dissolving oral formulations for critical drugs
RU2519768C2 (ru) * 2008-06-20 2014-06-20 Мерк Патент Гмбх Поддающаяся прямому прессованию и быстро распадающаяся матрица таблетки
FR2933299B1 (fr) 2008-07-04 2012-02-03 Roquette Freres Mannitol orodispersible
EP2385769A4 (en) * 2008-12-15 2014-08-20 Valeant Pharmaceuticals Luxembourg S R L QUICKLY SOLUBLE VITAMIN FORMULATION AND METHOD FOR THEIR USE
US20110027374A1 (en) * 2008-12-16 2011-02-03 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US8080584B2 (en) 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
AU2010223105B2 (en) 2009-03-09 2016-05-12 Spi Pharma, Inc. Highly compactable and durable direct compression excipients and excipient systems
US20120077888A1 (en) * 2009-03-26 2012-03-29 Royal College Of Surgeons In Ireland Orodispersible tablets
PL2238974T3 (pl) * 2009-04-09 2013-09-30 E Pharma Trento S P A Granulat do stosowania w preparatach tabletek ulegających rozpadowi w ustach
US20100285164A1 (en) 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
US8497290B2 (en) * 2009-05-27 2013-07-30 Takeda Pharmaceuticals U.S.A., Inc. Thiocolchicine derivatives, method of making and methods of use thereof
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20120114717A1 (en) * 2009-07-10 2012-05-10 Merck Patent Gesellschaft Mit Beschrankter Haftung Tableting agent having a low water content, and method for the production thereof
JP6038651B2 (ja) * 2009-07-10 2016-12-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 錠剤を製造するための組成物の調製方法
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
EP2493457B1 (en) * 2009-10-30 2017-08-09 IX Biopharma Ltd Fast dissolving solid dosage form
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
US20110178180A1 (en) * 2010-01-18 2011-07-21 Kurt Nielsen Deuterium-enriched colchicine, thiocolchicine, and derivatives thereof; methods of preparation; and use thereof
WO2011091114A2 (en) 2010-01-22 2011-07-28 Mutual Pharmaceutical Company, Inc. Thiocolchicine and colchicine analogs, methods of making and methods of use thereof
EP2384742A1 (en) 2010-05-03 2011-11-09 The Jordanian Pharmaceutical Manufacturing Co. Pharmaceutical excipient, method for its preparation and use thereof
JP6173912B2 (ja) 2010-09-20 2017-08-02 エスピーアイ ファーマ,インコーポレイテッド マイクロカプセル化プロセスおよび製品
AU2012241189A1 (en) * 2010-10-26 2014-04-24 Ix Biopharma Pte Ltd Fast Dissolving Solid Dosage Form
CN103384517A (zh) 2010-12-22 2013-11-06 巴斯夫欧洲公司 快速崩解的固体包衣剂型
US8715729B2 (en) 2010-12-22 2014-05-06 Basf Se Rapidly disintegrating, solid coated dosage form
JP2014507454A (ja) * 2011-03-09 2014-03-27 ビーエーエスエフ ソシエタス・ヨーロピア 速崩錠を製造するための医薬製剤
US9265757B2 (en) 2011-08-25 2016-02-23 Aptapharma Inc. Methods of administering antihistamines
IN2014DN06995A (enExample) * 2012-02-22 2015-04-10 Toyama Chemical Co Ltd
US20150140097A1 (en) 2012-04-25 2015-05-21 Spi Pharma, Inc. Crystalline microspheres and the process for manufacturing the same
WO2013171164A1 (en) 2012-05-14 2013-11-21 EJP Pharmaceutical ApS Compositions and formulations for the treatment of halitosis
FI126168B (en) * 2012-09-18 2016-07-29 Novaldmedical Ltd Oy A method for coating pharmaceutical substrates
NZ706302A (en) * 2012-10-11 2017-07-28 Ix Biopharma Ltd Sublingual wafer solid dosage form containing amylopectin
EP2922552A1 (de) 2012-11-22 2015-09-30 Bayer Pharma Aktiengesellschaft Verwendung und anwendungsregime einer pharmazeutischen zusammensetzung enthaltend levonorgestrel und einen cox-inhibitor zur bedarfsweisen ("on-demand") kontrazeption
US20160242439A1 (en) 2014-04-04 2016-08-25 Douxmatok Ltd Method for producing sweetener compositions and sweetener compositions
US10231476B2 (en) 2014-04-04 2019-03-19 Douxmatok Ltd Sweetener compositions and foods, beverages, and consumable products made thereof
US10207004B2 (en) 2014-04-04 2019-02-19 Douxmatok Ltd Method for producing sweetener compositions and sweetener compositions
EP3206671B1 (en) 2014-10-16 2024-06-12 Cargill, Incorporated Process for preparing a directly compressible erythritol and uses thereof
FR3038836B1 (fr) * 2015-07-17 2017-07-14 Roquette Freres Granules de mannitol pour compression directe
EP3135272A1 (en) 2015-08-31 2017-03-01 Basf S.A. Compositions for mouth wash in the form of tablets
BR112018017173A2 (pt) 2016-02-23 2019-01-02 Univ Colorado Regents composições e métodos para a produção e uso de formulações imunogênicas termoestáveis com compatibilidade aumentada de uso como vacinas contra um ou mais patógenos
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10064820B2 (en) 2016-09-30 2018-09-04 Aptapharma Inc. Antihistamine compositions, combinations, and use thereof
CN111712235A (zh) 2018-01-16 2020-09-25 应用材料公司 金属氧化物包封的药物组合物及其制备方法
WO2020018845A1 (en) * 2018-07-18 2020-01-23 Anewsha Holding Group Llc Rapidly dissolving pharmaceutical compositions and method of manufacturing
EP4021423A4 (en) 2019-08-27 2023-11-08 Applied Materials, Inc. Vapor phase coating technology for pharmaceutical abuse deterrent formulations
US11464827B2 (en) 2020-03-10 2022-10-11 Anewsha Holding Group Llc Antiviral pharmaceutical compositions and method of manufacturing
WO2021231946A1 (en) * 2020-05-15 2021-11-18 Spi Pharma, Inc. Compositions and methods for hardening
TWI870622B (zh) 2020-10-02 2025-01-21 美商應用材料股份有限公司 製備氧化矽塗佈藥品的低溫處理
US12491165B2 (en) 2021-09-30 2025-12-09 Applied Materials, Inc. Low temperature silicon oxide coating for pharmaceutical applications

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3145146A (en) 1961-10-31 1964-08-18 Warner Lambert Pharmaceutical Modified mannitol for pharmaceutical tablets
DE3245170A1 (de) 1982-12-07 1984-06-07 Merck Patent Gmbh, 6100 Darmstadt Verbesserter sorbit, verfahren zur herstellung und verwendung
US4832956A (en) 1985-09-25 1989-05-23 Gerhard Gergely Disintegrating tablet and process for its preparation
US4990537A (en) 1988-07-11 1991-02-05 Banyu Pharmaceutical Co., Ltd. Anti influenza agent
ATE107854T1 (de) 1988-09-30 1994-07-15 Rhone Poulenc Rorer Ltd Pharmazeutisches granulat.
US5583215A (en) 1990-06-25 1996-12-10 Towa Chemical Industry Co., Ltd. Crystalline mixture solid containing maltitol and a process for preparing it
IE67345B1 (en) 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
DE69331839T2 (de) 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
FR2710637B1 (fr) 1993-09-28 1995-12-08 Roquette Freres Mannitol pulvérulent de friabilité modérée et son procédé de préparation.
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5635210A (en) * 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
DE4439858A1 (de) 1994-11-08 1996-05-09 Merck Patent Gmbh Durch Co-Sprühtrocknung erhältliche Polyol-Zusammensetzung
DE19615418A1 (de) 1996-04-22 1997-10-23 Merck Patent Gmbh Polyol-Zusammensetzung
DE19617487A1 (de) 1996-05-02 1997-11-06 Merck Patent Gmbh Geschmacksverbesserung von Arzneimittelwirkstoffen
US5957471A (en) * 1996-10-28 1999-09-28 Weeks; Bruce V. Snow vehicle
US5958453A (en) 1996-10-31 1999-09-28 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility
US6274727B1 (en) 1996-11-15 2001-08-14 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for producing shaped and unshaped polyol masses
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
NZ337749A (en) 1997-05-01 2000-09-29 Nissan Chemical Ind Ltd Benzimidazole derivative and their use in allergy-related disease
FR2766089B1 (fr) 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
WO1999018935A1 (de) 1997-10-15 1999-04-22 Merck Patent Gmbh Herstellung eines direkt verpressbaren tablettierhilfsstoffes
FI107732B (fi) * 1998-03-18 2001-09-28 Xyrofin Oy Laktitolin kiteyttäminen, kiteinen laktitolituote ja sen käyttö
DE19820957A1 (de) 1998-05-11 1999-11-25 Merck Patent Gmbh Verfahren zur Herstellung von Mannit
GT199900061A (es) 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
WO2000057857A1 (en) 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
US20020071864A1 (en) 1999-03-25 2002-06-13 Yuhan Corporation Rapidly disintegrable tablet for oral administration
DE19927537A1 (de) 1999-06-16 2000-12-21 Merck Patent Gmbh Sprühtrocknungsanlage und Verfahren zu ihrer Verwendung
WO2000078292A1 (en) 1999-06-18 2000-12-28 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6248359B1 (en) * 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
WO2002015880A2 (en) 2000-08-25 2002-02-28 Merck Patent Gmbh Powdered mannitol and mannitol-containing compositions
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
US6814978B2 (en) * 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
EP1369131A1 (en) 2001-03-06 2003-12-10 Kyowa Hakko Kogyo Co., Ltd. Utilization of spray-dried powder containing sugar alcohol
EP1369109A1 (en) 2001-03-06 2003-12-10 Kyowa Hakko Kogyo Co., Ltd. Preparations quickly disintegrating in oral cavity
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
DE10161402A1 (de) 2001-12-13 2003-06-18 Merck Patent Gmbh Verfahren zur Herstellung von direkt tablettierbarem beta-Mannit
US7118765B2 (en) * 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms

Also Published As

Publication number Publication date
EP1465604A1 (en) 2004-10-13
EP1465604A4 (en) 2006-11-08
ZA200404998B (en) 2005-07-27
US9138413B2 (en) 2015-09-22
AU2002351396A1 (en) 2003-06-30
AU2002351396B2 (en) 2008-09-25
WO2003051338A1 (en) 2003-06-26
US20060251716A1 (en) 2006-11-09
US20140023707A1 (en) 2014-01-23
HK1067544A1 (en) 2005-04-15
US20030118642A1 (en) 2003-06-26
EP1465604B1 (en) 2013-07-17
CA2470601A1 (en) 2003-06-26
US20160051680A1 (en) 2016-02-25
JP2005520796A (ja) 2005-07-14
CA2470601C (en) 2012-10-02
US8545889B2 (en) 2013-10-01
MXPA04005955A (es) 2005-03-31
ES2429529T3 (es) 2013-11-15
US10702605B2 (en) 2020-07-07
US7118765B2 (en) 2006-10-10

Similar Documents

Publication Publication Date Title
JP4472988B2 (ja) 固体剤形用の速溶性マトリックスとしての同時処理炭水化物の系
CN101460150B (zh) 用于口腔崩解片剂的可直接压片复合物
EP2405905B1 (en) Highly compactable and durable direct compression excipients and excipient systems
KR101626873B1 (ko) 구강붕해정제
JP5248469B2 (ja) 口腔内速崩壊性医薬組成物およびその製造方法
CN1239151C (zh) 口腔内快速崩解片剂
EP2367540B1 (en) Oral dispersible tablet
CN103402497A (zh) 快速分散颗粒、口腔崩解片以及方法
JPWO2002002083A1 (ja) 口腔内速崩壊錠およびその製造法
JP2004315483A (ja) 口腔内崩壊錠剤
JPWO2018124062A1 (ja) 含量均一性を改善した製剤の製造方法
JP7742738B2 (ja) イブプロフェンとトラネキサム酸を含有する錠剤及びその製造方法
CN115175670B (zh) 羟基氧化铁(iii)、蔗糖和一种或更多种淀粉的混合物的颗粒,优选羟基氧化蔗糖铁的颗粒
HK1067544B (en) Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
HK1166024B (en) Highly compactable and durable direct compression excipients and excipient systems

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091102

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091202

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100301

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100304

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130312

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4472988

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140312

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term